JHVEPhoto/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday.
Omvoh is now indicated for both forms of inflammatory bowel disease, including ulcerative colitis.
Health Canada has also approved a